Genomic Valley Biotech Ltd (GVBL) is currently trading at 28.88 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Genomic Valley Biotech Limited specializes in biotechnology research, focusing on plant and animal biotechnology, and commercial production of plant tissue-cultured plants for the genetically improved plant market both domestically and internationally. The company is engaged in high-tech cultivation through controlled environment poly houses and other advanced methods such as NFT and DFT, along with the manufacturing of improved plant varieties using tissue culture methods. The company is actively involved in horticulture activities, cultivating a wide range of fruits and vegetables, and extends its expertise to farmers through training and consultancy services. Genomic Valley Biotech is setting up a Farmers Producer Company to enhance economic returns for small and marginal farmers, indicating a strong commitment to integrating and uplifting agricultural communities. The company assures market support for clients by taking turnkey projects on client land with guaranteed buy-back and marketing assurance, highlighting its role as a comprehensive agri-business solution provider.

Over the past 52 weeks, Genomic Valley Biotech Ltd has traded between a low of ₹20.10 and a high of ₹38.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Genomic Valley Biotech Ltd has a market capitalization of approximately 8.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Genomic Valley Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 412.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8.82 Cr, Genomic Valley Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Genomic Valley Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Genomic Valley Biotech Ltd is 412.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.